HB ZURICH / NEW YORK / LONDON. According to dealers has been speculation in the markets that the British pharmaceutical giant Glaxo-SmithKline-72 Swiss francs per ActelionShares could offer. ActelionShares closed 6.6 percent higher at 53 francs. The titles have gained this month, more than 30 percent.
Neither Actelion more Glaxo wanted to comment on the new market rumors. A person familiar with the situation told Reuters, however, Glaxo was not involved in a takeover of Actelion interested. The Swiss work together with Glaxo the sleeping pill almorexant.
On Wednesday, Reuters learned from a familiar person with the matter, Actelion was close to the obligations of the investment bank Moelis & Co as a consultant and will probably also Credit Suisse Seek advice.
According to analysts, are also Bristol-Myers Squibb, Amgen, Roche, Astra-Zeneca, Novartis and Bayer as potential buyers of Actelion question.
Actelion available sources said shortly before the commitment of the investment bank Moelis & Co as a consultant, reports the Reuters news agency. Moreover, it is likely that Actelion also in the Credit Suisse Search Council, said on Wednesday in circles familiar with the situation, according to Reuters.
Actelion declined to comment, as Moelis. In Credit Suisse first opinion was to get.